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Chitotriosidase enzyme (EC: 3.2.1.14) is the major active chitinase in the human body. It is produced mainly by activated
macrophages, in which its expression is regulated by multiple intrinsic and extrinsic signals. Chitotriosidase was confirmed
as essential element in the innate immunity against chitin containing organisms such as fungi and protozoa; however, its
immunomodulatory effects extend far beyond innate immunity. In the current review,wewill try to explore the expanding spectrum
of immunological roles played by chitotriosidase enzyme in human health and disease and will discuss its up-to-date clinical value.
1. Introduction
Chitotriosidase enzyme (CHIT1, EC: 3.2.1.14), belonging to
the family of 18 glycosyl hydrolases, was the first active
chitinase to be discovered in human plasma [1]. Its natural
substrate chitin is the second most abundant polysaccharide
in nature after cellulose. Chitin is the linear polymer of
N-acetylglucosamine and the main component of the cell
walls of fungi and protozoa, egg shells of helminthes, and
the exoskeletons of arthropods and insects; however, it is
completely absent in mammals [2]. Several protein members
of the same family were later detected in human plasma and
tissues including the enzymatically active acidic mammalian
chitinase (AMCase) [3] and chi-lectins, those having a chitin
binding domain with no catalytic activity such as chitinase-3
like-1 protein (CHI3L1 or YKL-40), chitinase-3 like-2 protein
(CHI3L2 or YKL-39), and oviductal glycoprotein-1 (OVGP1)
[4].
In man, chitotriosidase is mainly expressed by different
lineages of activated blood and tissue macrophages [5–10]
and to a lesser extent by polymorphonuclear leucocytes
[11]. The absence of its substrate chitin in the human body
and the exclusive production by immunologically active
cells immediately elicited the investigation of chitotriosidase
involvement in the innate immunity against chitin coated
pathogens [12]. Chitotriosidase was confirmed as an essential
factor for the defense against many such organisms as Plas-
modium falciparum [13], Wuchereria bancrofti [14], Candida
albicans [15], Madurella mycetomatis [16], and Cryptococcus
neoformans [17].
The role of chitotriosidase enzyme inside macrophages
is not limited to its chitinolytic activity against the engulfed
chitin containing organisms, or even to innate immunity.
It has been implicated in the activation and polarization
cascades of macrophages, as well as the indirect activation
of other immune cells such as T helper cells and eosinophils
[17–19]. Recent studies are interested in its immunomod-
ulatory effects through the processes of chitin recognition,
antigen presentation, induction of cell mediated immunity
and synergistic effects with proteases, and other enzymes to
kill different types of pathogens and cancer cells [10, 17–20].
On the other hand, chitotriosidase has been implicated in the
pathogenesis of many human diseases through the improper
induction of inflammation and faulty tissue remodeling such
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Figure 1: Schematic representation of human chromosome 1, CHIT1 gene on chromosome 1q32 locus, and the common 24-bp duplication
mutation at exon 10 of the CHIT1 gene.
as bronchial asthma, chronic obstructive pulmonary disease
(COPD), nonalcoholic fatty liver disease, and neurodegen-
erative disorders like Alzheimer’s disease and amyotrophic
lateral sclerosis [19, 21–24].
In the current review, we will provide a summary of
basic information about the enzyme and we will discuss its
immunomodulatory effects in humans over both innate and
acquired immunity together with its current and possible
future clinical applications.
2. Genetics
All the genes encoding active chitinases and chitinase-like
proteins are clustered in two loci on the human chromosome
1 (1p13 and 1q32). This genetic clustering displays a high
degree of conservation among different mammals indicating
an evolutionary relationship through common ancestral gene
duplication events [4].
The human chitotriosidase gene (CHIT1), extending over
20 kilobases at locus 1q32, consists of 12 exons translating a
466-amino acid protein [5, 25]. A common 24-bp duplication
mutation in exon 10 of the CHIT1 gene (Figure 1), leading to
alternate splicing and in-frame deletion of 87 nucleotides (29
amino acids), is responsible for almost all detected enzyme
deficiencies in different populations when homozygously
mutated [25, 26]. Although the mutated 24-bp duplication
allele is fairly common in Caucasian individuals (4–6%
homozygous and 30–50% heterozygous), it is extremely rare
in Sub-Saharan African individuals (0–2% only heterozy-
gous), suggesting the evolutionary advantage of keeping the
wild type enzyme in areas with high degrees of endemic
parasitic and fungal disease loads [26]. Interestingly, the
24-bp duplication mutation is much more common in the
Far East in populations of Japanese, Chinese, and Korean
ancestries as almost 30% of them are homozygous, while 50%
are heterozygous for the mutation [27, 28].
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Other relatively common functional mutations have been
also reported in the CHIT1 gene like G102S, G354R, and
A442V; however, when homozygously mutated, they are only
associated withmild to moderate decrease in enzyme activity
[27].
3. Chemistry and Modes of Action
Chitotriosidase enzyme has twomajor forms (a 50-kilodalton
form dominant in blood stream and a 39-kilodalton form
dominant in tissues), both having equal chitinolytic activities.
The 50-kilodalton protein (466 amino acids) is initially
produced by macrophages containing the 39-kilodalton N-
terminus having the catalytic domain and the C-terminus
having the chitin-binding domain connected together by a
short hinge region. The 39-kilodalton protein (387 amino
acids) is either cleaved post-translationally in the lysosome of
macrophages or less commonly formed through differential
RNA processing [25].
The enzyme was initially thought to be an exochitinase
because it can hydrolyze chitotriose residues and was termed
chitotriosidase based on this observation. However, recent
structural and binding modes studies revealed the enzyme to
be more of an endochitinase rather than an exochitinase [29,
30]. Furthermore, the strong binding affinity of chitotriosi-
dase to its substrate is also responsible for the relatively high
transglycosylation activity of the enzyme even in the absence
of excess substrate concentrations, making chitotriosidase a
complete independent chitinolytic machinery, and this is in
accordance with its anticipated physiological role as a potent
immunological defenseweapon againstmicroorganisms con-
taining chitin [31, 32].
4. Stimulatory Signals
Although chitotriosidase enzyme is relatively recently linked
to human pathology, many aspects of its intracellular
and extracellular mechanistic actions, effector and affec-
tor molecules, and diseases influenced by the increase or
decrease of its expression have been investigated. After its
initial association with innate immunity against chitin coated
pathogens it was rapidly identified as one of the major
protein products of activated macrophages and hence an
important nonspecific marker of macrophage activation [12].
Chitotriosidase activity was several hundred-fold elevated in
the plasma of patientswith the inflammatory based lysosomal
storage disorder Gaucher’s disease [1], in which macrophages
play an essential role in the clearance of the disease sphin-
golipid storagematerial.The lipid ladenmacrophage becomes
the disease histopathological pathognomonic cell in the bone
marrow and tissues or what is known as the Gaucher cell.
Furthermore, chitotriosidase is significantly elevated in some
infections caused by bacterial and viral pathogens lacking its
natural substrate chitin [33, 34].
Several intracellular pathways have been proposed to
explain the stimulatory molecules and the activation cas-
cades of chitotriosidase enzyme inside human macrophages.
Figure 2 provides a simple schematic representation of a
macrophage with different proposed stimulatory signals for
chitotriosidase expression as well as some of the main intra-
and intercellular activities of the enzyme.
Chitin naturally is a potent activator of chitotriosidase
expression, either phagocytized by themacrophage in the cell
walls of different fungi and protozoa or directly introduced
to macrophages through an unidentified receptor [35, 36].
Chitin and its small hydrolyzed particles when cocultured
with macrophages can stimulate the production of TNF-𝛼
and IFN-𝛾 [37] which can both increase the expression and
activity of chitotriosidase enzyme inside macrophages [38].
Lipopolysaccharide (LPS) which is an important component
of the bacterial cell wall was also confirmed as a potent
stimulant of chitotriosidase transcriptionmainly through the
NF-𝜅B signaling pathway [38, 39], which is also responsible
for exerting the effects of TNF-𝛼; however, IFN-𝛾 most
probably produces its effect through stimulating the Jak-
Stat signaling pathway [40]. Another possible mechanism of
chitotriosidase activation by bacteria is through the bacterial
peptidoglycan productmuramyl dipeptide (MDP), activating
the NOD2 signaling pathway which is also implicated in
the expression of chitotriosidase enzyme inside macrophages
[41, 42].
Prolactin hormone which is structurally related to many
human cytokines and is involved in the regulation of
monocyte/macrophage functions was also shown to increase
macrophage chitotriosidase production [43].Through study-
ing signal pathway inhibitors, prolactin was shown to stim-
ulate chitotriosidase expression through multiple signaling
pathways including the mitogen activated protein kinase
(MAPK), PI3 kinase (PI3K/Akt), and the protein tyrosine
kinase (PTK) pathways [44].
The inflammasome system is also expected to play some
role in the activation of chitotriosidase expression as both
ingested bacterial MDP and cystine crystals can stimulate
macrophages through the NLRP3 inflammasome system [45,
46], leading eventually to the production of IL-1𝛽, which
either can stimulate the NF-𝜅B signaling pathway directly
or indirectly induces the production of TNF-𝛼 [47], thus
stimulating the expression of chitotriosidase.
Another efficient way to activatemacrophages and induce
chitotriosidase expression is through the paracrine effect
of natural killer cells (NK cells), which when exposed to
cells infected with viral, bacterial, or fungal pathogens or
even neoplastic cells can produce large amounts of INF-𝛾
and TNF-𝛼 [36, 48] in the vicinity of macrophages, both
increasing the expression and release of chitotriosidase.
5. Immunological Effects and
Clinical Perspectives
Chitotriosidase enzyme expression increases exponentially
during the normal monocyte to macrophage maturation
process showing a peak of expression between the 5th day
and the 7th day of culture [18] and is recently detected to be
expressed in both macrophage polarization forms (M1 and
M2). M1 macrophages, or classically activated macrophages,
are mainly directed to promote inflammation, kill the
invading pathogens. and stimulate tissue fibrosis following
injury. On the other hand, M2 macrophages, or alternatively
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Figure 2: Schematic representation of a human macrophage showing different stimuli leading to the increased expression and release
of chitotriosidase enzyme. An elaborate description of the processes implicated in increased chitotriosidase expression, as well as its
immunological effects, is provided in the text. 39-KD chito: chitotriosidase (39 kilodalton protein); 50KD-chito: chitotriosidase (50 kilodalton
protein); ERK1/2: extracellular signal regulated kinases 1/2; IL-1𝛽: interleukin-1𝛽; IL-18: interleukin-18; INF-𝛾: interferon-gamma; Jak:
Janus kinase; LPS: lipopolysaccharide; MAPK: mitogen activated protein kinase; MCP-1: monocyte chemotactic protein-1; MDP: muramyl
dipeptide; NF-𝜅B: nuclear factor-kB; NK cell: natural killer cell; NLRP3: NOD-like receptor family, pyrin domain containing 3; NO: nitric
oxide; NOD2: nucleotide-binding oligomerization domain-containing protein 2; PI3K: PI3 kinase; PTK: protein tyrosine kinase; RANTES:
regulated on activation, normal T cell expressed and secreted; Stat; signal transducers and activators of transcription; TGF-𝛽: transforming
growth factor-beta; Th2 cell: T helper type 2 cell; TNF-𝛼: tumor necrosis factor-alpha.
activated macrophages, provide regulatory signals to protect
the host from an exaggerated inflammatory response and
promote tissue remodeling and healing [49]. The fact that
chitotriosidase is expressed almost equally in both forms
denotes its regulatory roles over processes far beyond the
hydrolysis of chitin in pathogens. Further studies are still
needed to clarify the role of chitotriosidase enzyme in the
alternatively activated M2 macrophages.
Dendritic cells are themost important antigen presenting
cells in the human body and one of the members of the
monocyte/macrophage lineage. Although AMCase is widely
expressed in different tissues, especially in the epithelial cells
of the gastrointestinal tract and lungs [3], chitotriosidase was
the only implicated active chitinase in the process of chitin
recognition and antigen presentation [17]. Recent evidence
suggests that the induction of human T helper 2 cells (Th2)
in response to pulmonary cryptococcal infection is totally
dependent on chitin cleavage by chitotriosidase and that
CD11b+ conventional dendritic cells act as antigen presenting
cells for the specifically fragmented chitin products [17]. Fur-
thermore, chitotriosidase mRNA and protein concentrations
were significantly elevated in mature dendritic cells without
chitin sensitization as compared to immature dendritic cells
[10], implying that chitotriosidase might be also playing a
role in the process of antigen presentation regardless of the
presence of chitin.
Recently, activated macrophages and chitotriosidase ele-
vations were implicated in the pathogenesis of nephropathic
cystinosis, another lysosomal storage disorder characterized
by cystine crystal accumulation inside macrophages in dif-
ferent body organs. Cystine crystals in vitro when incubated
with human monocyte derived macrophages were able to
activate macrophages in a concentration dependent manner
evidenced by the increased concentrations of TNF-𝛼 and the
concomitant activities of chitotriosidase enzyme in culture
supernatant and in cell homogenate. Furthermore, plasma
chitotriosidase activities in cystinotic patients correlated
positively with leucocytes cystine concentrations, making
it a potential target for the disease therapeutic monitoring
[50]. Cystinosis was the first crystal based disease with
the confirmed involvement of chitotriosidase enzyme in its
pathogenesis, making it an interesting target to investigate in
other more common crystal related disorders such as gout
and hyperoxaluria.
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Table 1: Human diseases associated with elevated chitotriosidase enzyme.
Disease group Disease Proposed clinical value (sample type) References
Lysosomal storage diseases
Gaucher Screening, therapeutic monitoring (P/S) [1, 62]
Niemann-Pick A/B and C Screening, therapeutic monitoring (P/S) [65]
Cystinosis Therapeutic monitoring (P/S) [50]
Fabry Therapeutic monitoring (P/S) [66]
Krabbe Screening, marker of severity (P/S) [67]
Wolman Therapeutic monitoring (P/S) [68]
Farber Screening (P/S) [69]
GM1 Screening (P/S) [70]
Sialidosis type II Screening (P/S) [71]
Infectious diseases
Systemic fungal infections:
Candida albicans, Madurella
mycetomatis, and Cryptococcus
neoformans
Prognosis, therapeutic monitoring (P/S) [15–17]
Malaria Prognosis (P/S) [13]
Filariasis Screening (P/S) [14]
Tuberculosis Prognosis, therapeutic monitoring (P/S) [72]
Brucellosis Therapeutic monitoring (P/S) [73]
Leprosy Prognosis, therapeutic monitoring (P/S) [74]
Crimean-Congo hemorrhagic
fever
Prognosis (P/S) [34]
Respiratory diseases
Asthma Marker of severity (P/S) [19, 21]
COPD Marker of severity (P/S, BAL) [21, 51]
Interstitial lung disease Screening, marker of severity (BAL) [52, 75]
Endocrinological diseases Diabetes
Marker of endothelial damage (P/S) [76]
Marker of nephropathy progression (P/S) [53]
Cardiovascular diseases
Atherosclerosis Marker of severity (P/S) [77, 78]
Stroke Prognosis (P/S) [79]
Coronary artery disease Prognosis (P/S) [80]
Erectile dysfunction Marker of severity (P/S) [81]
Neurological diseases
Amyotrophic lateral sclerosis Screening, marker of severity (P/S, CSF) [24, 82]
Alzheimer’s disease Prognosis, marker of severity (CSF) [23, 83]
Cerebral adrenoleukodystrophy Prognosis (P/S, CSF) [84]
Neuromyelitis optica Screening (CSF) [50]
Multiple sclerosis Screening, prognosis (CSF) [50]
Gynecological and obstetrical diseases
PCOS Prognosis (P/S) [85]
Endometriosis Marker of severity (P/S) [86]
Preeclampsia Marker of fetal compromise (UC) [87]
Miscellaneous
NAFLD Marker of severity (P/S) [22]
FMF Screening, marker of severity (P/S) [88]
𝛽-Thalassemia Marker of severity, therapeutic monitoring (P/S) [89]
Sarcoidosis Marker of severity, therapeutic monitoring (P/S) [63]
Acute appendicitis Screening (P/S) [90]
Juvenile idiopathic arthritis Screening, marker of severity (SV) [91]
Prostate cancer Prognosis (P/S) [92]
BAL: bronchoalveolar lavage; COPD: chronic obstructive pulmonary disease; CSF: cerebrospinal fluid; FMF: familialMediterranean fever; GM1: gangliosidosis
M1; NAFLD: nonalcoholic fatty liver disease; PCOS: polycystic ovarian syndrome; P/S: plasma or serum; SV: synovial fluid; UC: umbilical cord blood.
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Chitotriosidase also mediates many inflammatory pro-
cesses through the direct stimulation of different inflamma-
tory mediators such as IL-8, MMP9 (collagenase type IV),
MCP-1 (CCL2), RANTES (CCL5), and eotaxin (CCL11), thus
increasing the migratory capacity of many immunological
cells including T lymphocytes, macrophages, and eosinophils
[51, 52]. Levels of chitotriosidase activities strongly corre-
lated with the concentrations of IL-1𝛽 and TNF-𝛼 in the
bronchoalveolar lavage (BAL) of COPD patients supporting
the hypothesis of a mutual regulation cascade in the pro-
duction of these inflammatory mediators [52]. Furthermore,
chitotriosidase was involved in the induction of fibrosis in the
murine model of interstitial lung disease as the bleomycin-
induced pulmonary fibrosis was significantly reduced in
𝐶ℎ𝑖𝑡1−/− mice and significantly enhanced in lungs from Chit1
overexpressing transgenic mice. This effect is explained by
the activation of fibroblasts through enhancing TGF-𝛽 and
increasing the expression of TGF-𝛽 receptors 1 and 2 leading
to the activation of the Smad and MAPK/ERK signaling
pathways [53]. Similar effects have been clinically observed
with other human diseases characterized by faulty tissue
remodeling and abnormal healing such as nonalcoholic fatty
liver disease, bronchial asthma, and diabetic nephropathy
in which chitotriosidase plasma activities strongly correlated
with disease progression and/or the degree of tissue fibrosis
[21, 22, 54]. Targeting the chitotriosidase activation cascade
through the administration of specific antibodies or pan-
chitinase inhibitors significantly ameliorates inflammation
and fibrosis in several animal models of autoimmune dis-
eases, most likely by suppressing the chitotriosidase depen-
dent release of different cytokines and chemokines [55];
however, the safety of this approach in humans is not yet
determined as it might increase the susceptibility to fungal
and protozoal infections.
Chitinases and chi-lectins could play a detrimental role
in human cancer development, especially CHI3L1 (YKL-40)
which has been associatedwith increased tumor angiogenesis
and bad prognosis in many human neoplasms such as breast,
lung, and cervical cancers [56–58]. On the other hand,
chitinases are also believed to have some anticancer cell
activities [59]. Macrophages were always considered as a
primary defense line against neoplastic cells, but the exact
mechanisms beyond this action were not very clear [60].
Speculations were made about a combined effect of released
NO and H
2
O
2
; however, there was no much evidence to
support this hypothesis [20]. Recently, bacterial and human
chitinases were both confirmed as having strong synergistic
effects with protease enzymes produced by macrophages
to dissolve mucin [61]. This mucolytic activity selectively
attacked the altered mucin in the cancer cell wall of animal
models and not the healthy cell mucin [59]. It is too early
to speculate about the therapeutic applications of this obser-
vation as many explanatory mechanistic studies are needed
to determine the specificity and the exact molecular and
chemical targets of this process.
Chitotriosidase is currently an established or a candidate
screeningmarker, severitymarker, and/or therapeuticmonitor
for over 40 different diseases, inherited and acquired. Table 1
provides a summary of human diseases clinically associated
with macrophage activation and chitotriosidase enzyme pro-
duction. Being a nonspecific marker of macrophage activa-
tion and deficient in about 6% of normal population clearly
limits chitotriosidase usability as a screeningmarker formany
diseases; however, in established diagnosed nondeficient
patients, chitotriosidase is an excellent marker to monitor
compliance and response to treatment [62, 63], especially
when the treatment targets inflammatory pathways. And in
some diseases its marked elevations made it also a quite
beneficial screening marker as in Gaucher’s disease even
when other lysosomal storage disorders are suspected [64].
6. Conclusions
Being a sensitive biomarker of macrophage activation, chi-
totriosidase activity is currently more and more commonly
used in clinical practice to evaluate the status and response
to treatment of inflammatory based diseases in which
macrophages play a significant role. The interesting mixture
of harmful and beneficial immunological effectsmade human
chitinases and chitotriosidase enzyme an intriguing point
of research. If proven safe in humans, the development of
targeted therapies either to suppress chitotriosidase activity
in autoimmune and inflammatory disorders, or to specifically
enhance its targeted activity to kill cancer cells or to potentiate
immunity against certain infections will not be far in the
future.
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